Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

Fig. 4

Mean change in mTSS from baseline at week 24 and week 52 (95% CI)—MOBILITY. All patients received weekly MTX, and sarilumab or placebo were administered q2w. At week 52, low Hb: P < 0.001 by rank ANCOVA for each sarilumab dose vs. placebo; normal Hb: rank ANCOVA P < 0.001 for 200 mg and P < 0.01 for 150 mg sarilumab dose vs. placebo. Hb, hemoglobin; mTSS, Modified Total Sharp Score; MTX, methotrexate; q2w, every 2 weeks; SD, standard deviation

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us